Pharmaceuticals & Medical Devices Non-Executive Recruitment

Few sectors combine regulatory intensity, scientific complexity and commercial pressure the way pharmaceuticals and medical devices do. A board in this sector must govern clinical-trial risk, regulatory approval pathways, post-market surveillance obligations, intellectual property and the sheer capital intensity of bringing a product to market — often years before revenue arrives. Non-Executive Directors here need more than general boardroom experience; they need genuine credibility on the scientific, regulatory and commercial questions the board must answer.

NED Capital places Non-Executive Directors into pharmaceutical, biotech and medical-device businesses — from clinical-stage companies and university spin-outs to the UK subsidiaries of international groups. Every candidate is assessed on both technical credibility and boardroom effectiveness, and every search is led personally by Adrian Lawrence FCA. Boards frequently pair this with board-level recruitment across the wider leadership team.

What Life Sciences Boards Require

Regulatory and clinical governance

The defining feature of a life sciences board is regulatory exposure. Directors must understand the MHRA approval pathway, the equivalent expectations of the EMA and FDA for companies with international ambitions, clinical-trial governance and the post-market surveillance obligations that continue long after approval. A NED who can interrogate a regulatory strategy or a trial design from a position of real knowledge is far more valuable than one who can only take management’s assurances on trust.

Commercial and licensing judgement

Scientific promise does not automatically become commercial success. Life sciences NEDs must be able to challenge R&D investment decisions, licensing and partnering strategy, pricing and market-access plans, and the timing of international expansion. The best combine scientific or regulatory literacy with hard commercial judgement about where value is actually created.

Financing and capital strategy

Clinical-stage businesses consume capital for years before profitability. Non-executives must understand the financing lifecycle — funding rounds, grant income, milestone payments, partnering deals and, where relevant, public-market listing — and provide oversight of cash runway and dilution. Financial discipline in a pre-revenue business is a distinct and demanding governance skill.

The Profiles We Represent

Our life sciences network includes former pharmaceutical and biotech executives, regulatory-affairs and clinical-development leaders, medical-device commercialisation specialists, and finance-qualified directors with life sciences experience who can chair audit committees in a capital-intensive, pre-revenue context. Many hold or have held non-executive roles on the boards of listed, PE-backed and venture-funded life sciences businesses, and understand the specific governance demands of each ownership model. For venture and PE-backed businesses in particular, our NEDs for private equity boards service applies the additional lens of investor-backed governance.

Our Approach

We begin with the board’s specific need — the stage of the business, the regulatory and clinical context, the financing position and the capability gap on the board. We then assess candidates against that brief rather than a generic template: regulatory and clinical credibility, commercial and licensing judgement, financing sophistication, and the independence and boardroom behaviour that make a non-executive effective. We operate in line with the voluntary code of conduct for executive search firms.

Related Services

NED Capital | Sister practice of FD Capital | ICAEW practising certificate held by Adrian Lawrence FCA.